The Medical Need

Surgery is the primary treatment option for many types of early-stage cancer. However, surgery is very often unsuccessful, resulting in the need for multiple operations or increasing the need for additional drug treatment or radiotherapy after surgery. For example, approximately 25% of patients undergoing surgery for prostate cancer will have a positive surgical margin which is an indicator of incomplete cancer removal. In breast cancer, approximately 20% of patients who undergo breast-conserving surgery will require an immediate re-operation

Surgery is unsuccessful so often because surgeons lack a tool to detect cancerous tissue in real time during surgery. Today, surgeons rely primarily on visual and manual assessment to find cancerous tissue during surgery.

There’s a pressing medical need to accurately differentiate cancerous and healthy tissue intra-operatively.  Lightpoint Medical’s technology brings molecular imaging into the operating room in order to address this medical need.


The Technology

Lightpoint Medical’s technology has the potential to detect cancer in real-time during surgery. The patient is injected with a cancer-targeted imaging drug which seeks out the cancerous tissue. The imaging drug then gives off a light signal or particle emission that can be detected by Lightpoint’s technology. The company has three products: The LightPath® Imaging System (CE Mark) for intraoperative specimen analysis and SENSEI® for robotic laparoscopic surgery.